XBI - Horizon Therapeutics: This Stock Has A 'Very Bullish' Rating By Both SA Quant Rating Tool And Wall Street Analysts
- The stock price performance of HZNP has been one of the best in the biotech universe year to date.
- The launch of Tepezza has been probably the best in the rare disease space ever.
- The stock price might be negatively impacted by the second wave of lockdown restrictions in the U.S.
For further details see:
Horizon Therapeutics: This Stock Has A 'Very Bullish' Rating By Both SA Quant Rating Tool And Wall Street Analysts